Skip to content
10-K

Annual Report

Definium Therapeutics, Inc. DFTX

0001193125-26-076742

← back to feed
Filed
Feb 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 19, 2026 99.7M sh
Shares Diluted FY 2025 · Dec 31, 2025 89.33M sh
Shares Diluted FY 2025 · Dec 31, 2024 70.46M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$131.56M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$79.13M
Long Term Debt FY 2025 · Dec 31, 2025 $40.58M
Short Term Investments FY 2025 · Dec 31, 2025 $153.76M
Short Term Investments FY 2025 · Dec 31, 2024 $0
Cash And Equivalents FY 2025 · Dec 31, 2025 $257.84M
Cash And Equivalents FY 2025 · Dec 31, 2024 $273.74M
Stockholders Equity FY 2025 · Dec 31, 2025 $332.33M
Stockholders Equity FY 2025 · Dec 31, 2024 $241.45M
Stockholders Equity FY 2025 · Dec 31, 2023 $78.13M
Current Liabilities FY 2025 · Dec 31, 2025 $66.7M
Current Liabilities FY 2025 · Dec 31, 2024 $38.85M
Total Liabilities FY 2025 · Dec 31, 2025 $107.77M
Total Liabilities FY 2025 · Dec 31, 2024 $60.7M
Current Assets FY 2025 · Dec 31, 2025 $419.32M
Current Assets FY 2025 · Dec 31, 2024 $281.62M
Total Assets FY 2025 · Dec 31, 2025 $440.1M
Total Assets FY 2025 · Dec 31, 2024 $302.15M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.06
Eps Diluted FY 2025 · Dec 31, 2024 −$1.54
Eps Basic FY 2025 · Dec 31, 2025 −$2.06
Eps Basic FY 2025 · Dec 31, 2024 −$1.54
Sga Expense FY 2025 · Dec 31, 2025 $48.64M
Sga Expense FY 2025 · Dec 31, 2024 $38.62M
Rd Expense FY 2025 · Dec 31, 2025 $117.67M
Rd Expense FY 2025 · Dec 31, 2024 $65.3M
Net Income FY 2025 · Dec 31, 2025 −$183.79M
Net Income FY 2025 · Dec 31, 2024 −$108.68M
Operating Income FY 2025 · Dec 31, 2025 −$166.31M
Operating Income FY 2025 · Dec 31, 2024 −$103.92M